Amgen Inc.
AMGN · Nasdaq
- $410.95
- $225.55B
- Open
- —
- —
- $0.00 - $0.00
- $269.77 - $418.40
- —
- —
- 1.96M
About Amgen Inc.
Amgen is a biopharmaceutical drug manufacturer that earns revenue by selling prescription medicines. The supplied material identifies Repatha as a key commercial product, with second-quarter sales up 37%, but does not provide a segment-level revenue split or identify additional products. Its reported scale is $36.8 billion of FY2025 revenue and $7.7 billion of net income, up from $33.4 billion and $4.1 billion in FY2024. Second-quarter 2026 results show revenue growth and improved earnings, while management raises 2026 earnings guidance. The evidence does not quantify customer mix, geographic exposure, or product-level contributions.
Notable Price Movement
- Aug 3-7$410.956.69%
Amgen fell $3.08, or 0.78%, from $393.10 on July 28 to $390.02 on August 4. The stock dropped $5.46 on July 29, was unchanged July 30, and fell another $2.48 July 31 before reversing sharply with an $11.15 gain on August 4. The rebound followed second-quarter results showing improved profit and revenue growth, earnings and revenue beats of 12.32% and 6.52%, respectively, 37% growth in Repatha sales, and higher 2026 earnings guidance. Thus, the week reflected a material pre-earnings decline followed by a strong earnings-day recovery, but the rebound did not fully erase the earlier losses.
